[HTML][HTML] New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
[HTML][HTML] Real-world experience with CPX-351 in high-risk acute myeloid leukemia
Abstract CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with …
CPX-351 in FLT3-mutated acute myeloid leukemia
C Andrews, V Pullarkat, C Recher - Frontiers in Oncology, 2023 - frontiersin.org
CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a 1: 5
molar ratio, is approved for the treatment of newly diagnosed therapy-related acute myeloid …
molar ratio, is approved for the treatment of newly diagnosed therapy-related acute myeloid …
Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France
A Belhabri, M Heiblig, S Morisset, L Vila… - Cancer …, 2023 - Wiley Online Library
Background t‐AML occurs after a primary malignancy treatment and retains a poor
prognosis. Aims To determine the impact of primary malignancies, therapeutic strategies …
prognosis. Aims To determine the impact of primary malignancies, therapeutic strategies …
Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
T Bernal, AF Moreno, A De Laiglesia… - Cancer …, 2023 - Wiley Online Library
Background CPX‐351 is approved for the treatment of therapy related acute myeloid
leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits …
leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits …
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM …
Simple Summary CPX-351 has been approved for the treatment of adults with therapy-
related AML (t-AML) or AML with myelodysplasia-related changes (AML–MRC). The aim of …
related AML (t-AML) or AML with myelodysplasia-related changes (AML–MRC). The aim of …
[HTML][HTML] Real-world experience with CPX-351 treatment for acute myeloid leukemia in England: an analysis from the National Cancer Registration and Analysis …
A Legg, A Lambova, A Broe, J Levy… - … Lymphoma Myeloma and …, 2023 - Elsevier
Background CPX-351 demonstrated improved overall survival (OS) versus conventional 3+
7 daunorubicin/cytarabine chemotherapy in a registrational phase III study in older patients …
7 daunorubicin/cytarabine chemotherapy in a registrational phase III study in older patients …
Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia
JP Bewersdorf, AM Zeidan - Pathogenesis and Treatment of Leukemia, 2023 - Springer
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-
related AML (t-AML) are often combined under the term secondary AML (sAML) and are …
related AML (t-AML) are often combined under the term secondary AML (sAML) and are …
In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia
H Gill, A Yip - Pathogenesis and Treatment of Leukemia, 2023 - Springer
Acute myeloid leukaemia (AML) is an aggressive, heterogenous, and age-related
haematological malignancy with dismal prognosis. Conventional therapy for AML consists of …
haematological malignancy with dismal prognosis. Conventional therapy for AML consists of …
[HTML][HTML] Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years
D Chaudhuri, KI Khan, R Al Shouli, A Allakky… - Cureus, 2023 - ncbi.nlm.nih.gov
In myelodysplastic syndrome (MDS), neoplastic cells originate in hematopoietic stem cells of
the bone marrow, causing dysplasia in multiple cell lines. This may ultimately lead to …
the bone marrow, causing dysplasia in multiple cell lines. This may ultimately lead to …